Stemedica Cell Technologies, Inc. USA has applied for a patent application with the United States Patent and Trademark Office for a proprietary methodology in the treatment of diabetic retinopathy.

Stemedica’s invention relates to the use of multiple stem cells and a transplantation methodology in the treatment of diabetic retinopathy. Patients who participated have had varying degrees of diabetic retinopathy and diabetic optic neuropathy. These patients received neural progenitor cells by retrobulbar injection and mesenchymal stem cells by intravenous administration. The patients were observed at baseline and then after treatment at days 2, 8, 14, 30, 60, 90, and 120. Annual physical and ophthalmic examinations were conducted each year thereafter for a three year period.

The overall visual function improved in all eight patients within sixty days of treatment and there was a reduction in absolute scotomas. The results also showed increases in the thickness of the optic nerve fiber, resorption of hemorrhages, no new micro bleeding edema of the nerve fiber layer and a decrease in macular edema. None of the patients developed tumors, had impaired vision or experienced adverse health effects connected with the cell injections. Seven of the eight participating patients have maintained the overall vision improvements they gained from treatment three years later.

This patent application, Publication Number US2009/0214485 A1, is available for review via the USPTO at http://www.uspto.gov ^[1].

Read ^[2] the release.